Stay updated with breaking news from Histological Samples. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...
* Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial... | May 17, 2023
Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy ... | May 17, 2023
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease
Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer